Compare Natera Inc. Common Stock (NTRA) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Direxion Daily TSLA Bull 2X Shares trades at $9.29 (market cap $3.84B). The key difference: Natera Inc. Common Stock is far larger — about 14.9× Direxion Daily TSLA Bull 2X Shares's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| NTRA | TSLL | |
|---|---|---|
Market Cap | $57.03B | $3.84B |
Volume | 1,131,157 | 36,217,346 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $23.03 |
52-Week Low | $179.42 | $6.74 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.00, down 1.48% on the day, reflecting amplified exposure to Tesla's volatility. The technical outlook is mixed with a neutral overall signal, while recent news highlights its sensitivity to Tesla-specific catalysts like the Cybercab event. Financial ratios are not applicable as this is a leveraged ETF tracking Tesla's daily performance.
The outlook for TSLL is directly tied to Tesla's stock momentum, offering potential for magnified gains but carrying high risk from daily rebalancing and volatility decay. Investors face significant downside risk if Tesla trends lower, making it suitable only for short-term, risk-tolerant traders monitoring Tesla's news flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
